SODD (NT) Blocking Peptide

SODD (NT) Blocking Peptide

Product No.: S491

[product_table name="All Top" skus="S491"]

- -
- -
Target
SODD
Product Type
Blocking Peptide

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Product Concentration
0.2 mg/ml
Amino Acid Location
This peptide sequence is located at amino acids 2 to 16 of Human SODD protein.
Formulation
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Storage and Handling
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Background
Silencer of Death Domains peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

References & Citations

1. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995;270:13757-65 2. Huang J, Gao X, Li S, Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci U S A 1997;94:12829-32 3. Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem 1997;272:7727-31 4. Hofmeister R, Wiegmann K, Korherr C, Bernardo K, Kronke M, Falk W. Activation of acid sphingomyelinase by interleukin-1 (IL-1) requires the IL-1 receptor accessory protein. J Biol Chem 1997;272:27730-6 (RD1299)
- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.